Key result
Rosiglitazone and ramipril show no significant benefit over placebo for arterial stiffness measures.
RCT (n=33)
Double-blind
Randomized
Answers are grounded in this paper and cite their sources.
INTRODUCTION: The aim of the study is to investigate whether standard doses of rosiglitazone (4 mg/daily) and ramipril (5 mg/daily) can reverse pre-clinical macrovasculopathy in newly diagnosed never treated type 2 diabetes (T2DM) patients. METHODS: In this randomized, double-blind, placebo-controlled study, 33 T2DM patients were randomized to rosiglitazone (4 mg/daily) or ramipril (5 mg/daily) or placebo for 1 year. Hemodynamic variables were measured at 3 treatment phases and pulse wave velocity (PWV) and augmentation index (AI) were measured throughout the treatment period. RESULT: In diabetic patients, PWV (P = 0.037) and AI (P = 0.005) with ramipril and AI (P < 0.001) with rosiglitazone were significantly reduced during overall treatment period from the baseline; however, these differences were not significant in comparison to placebo. DISCUSSION AND CONCLUSION: The present study showed that treatment with standard doses of rosiglitazone and ramipril are not adequate to reverse pre-clinical vasculopathy in T2DM. The lack of benefit in newly diagnosed T2DM may be because of the relatively short-term intervention and/or the use of lower doses of rosiglitazone/ramipril. Further trials are needed for a longer period of time, possibly with higher doses, to show whether rosiglitazone/ramipril can reverse pre-clinical vasculopathy in T2DM (ClinicalTrials.gov number, NCT00489229).
No takes yet. Share an insight, caveat, or question.
Sayeeda Rahman (2010) conducted an RCT in Type 2 diabetes mellitus (T2DM) with pre-clinical macrovasculopathy (n=33). Rosiglitazone or ramipril vs. Placebo was evaluated on Pulse wave velocity (PWV) and augmentation index (AI) (p=not significant vs placebo (baseline reduction: ramipril PWV P=0.037, AI P=0.005; rosiglitazone AI P<0.001)). Rosiglitazone and ramipril reduced augmentation index from baseline, but differences vs placebo were not significant.
Synapse has enriched 10 related papers. Consider them for comparative context: